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patients. However, vaccine efﬁcacy is limited by effector cell dysfunc-
tion and increased presence of regulatory T cells characteristic of
cancer patients. Ligation of CD3/CD28 delivers an antigen-indepen-
dent stimulus to resting T cell populations. We postulated that stim-
ulation with DC/tumor fusions followed by anti-CD3/CD28 would
result in the signiﬁcant expansion of activated T cells targeting tumor
antigens. DCs were generated from adherent mononuclear cells cul-
tured with rhIL-4, GM-CSF and TNF and fused with RCC by
coculture in 50% solution of polyethylene glycol. T cells were stim-
ulated by DC/tumor fusions prior to or following exposure to an-
tiCD3/CD28 antibody coated plates for 48 hours. A dramatic, statis-
tically signiﬁcant, increase in T cell proliferation was observed
following the sequential exposure to DC/RCC fusions and anti-CD3/
CD28 (SI 13.2). In contrast, stimulation by anti-CD3/CD28, DC/
tumor fusions, or anti-CD3/CD28 followed by fusion cells did not
result in signiﬁcant T cell proliferation. Similarly, sequential stimula-
tion byDC/RCC fusion cells followed by anti-CD3/CD28 resulted in
a nearly 8 fold expansion of CD4/CD25 cells (n10, p0.001
compared to unstimulated T cells). A 16 fold increase in CD4/CD25/
CD69 cells was observed consistent with the expansion of activated
T cells. In contrast, exposure to anti-CD3/CD28 alone or anti-CD3/
CD28 followed by stimulation with fusion cells resulted in a 3 fold
expansion of CD4/CD25 T cells and a modest expansion of CD4/
CD25/CD69 cells. In concert with these ﬁndings, IFN production
by CD4 T cells was most pronounced following stimulation with
DC/tumor fusions and expansion with anti-CD3/CD28 (p.01). In 9
experiments, stimulation with DC/RCC fusions followed by expan-
sion with anti-CD3/CD28 also resulted in a 5-fold and 4.6 fold
expansion of CD4/CD25/Foxp3 and IL-10 expressing T cells, re-
spectively. In conclusion, we have demonstrated that stimulation of T
cells by DC/RCC fusions followed by exposure to anti-CD3/CD28
antibodies results in the expansion of tumor reactive T cells that
predominantly express markers of activation. We are developing a
clinical trial in which patients will receive fusion/CD3/CD28 ex-
panded T cells following in vivo depletion of regulatory T cells.
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Background:Despite advances in therapy, the survival for glioblas-
toma multiforme (GBM) has remained unchanged for 50 years. We
have investigated a cellular therapeutic therapy based on innate im-
mune recognition of GBM using ex vivo expanded  T cells that are
highly cytotoxic to GBM lines. Unlike 	CD8 cytotoxic T lym-
phocytes,  T cells act directly against stress-associated antigens
expressed on GBM and do not require MHC antigen recognition.
Methods: We examined the circulating  T cell number and
function in healthy controls and patients at speciﬁc times; diagnosis,
1-14 days post resection, and 8-14 weeks post resection. Absolute
lymphocyte and subset counts including  T cell counts were exam-
ined using ﬂow cytometry. Functional response of  T cells was
determined by proliferation in our clinically compliant expansion
procedure and subsequent in vitro and in vivo cytotoxicity assays.
Expansion cultures were harvested after two weeks and enriched for
 T cells by immunomagnetic depletion of CD4 and CD8 T
cells. Cytotoxicity of expanded T cells was evaluated in vitro against
GBM primary tumor cultures, established GBM cell lines and cul-
tured astrocytes. In vivo assays were conducted in athymic nude mice
against new and established luciferase-transduced human U251 GBM
xenografts.
Results: At diagnosis, the circulating  T cell count is not signif-
icantly less than controls (p  0.12). The absolute CD3 and CD4
count increase immediately after resection, likely due to removal of
GBM-derived immunosuppressive cytokines. Surprisingly however,
individual patients show a decrease in  T cell counts at this time.
Expansion of  T cells from pre-resection GBM patients did not
differ from controls (p  0.32, n4). although  T cell expansion
was signiﬁcantly impaired after cytoreductive therapy (p  .007,
n5). Expanded  T cells retain cytotoxicity against U251 and 1047
GBM cell lines and GBM primary cultures but spare normal astro-
cytes. Expanded  T cells slow the growth of U251 intracranial
xenografts in athymic nude mice (p .008) vs sham-treated controls.
Preliminary observations suggest that growth of established U251
xenografts is slowed in selected animals as well.
Conclusions: GBM and therapy-induced immunosuppression
present a formidable barrier to systemic cellular therapy. However,
intracranial immunotherapy using expanded allogeneic  T cells
represents a potentially effective immunotherapeutic strategy against
GBM.
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SEMI-HIGH-DOSE AUTOLOGOUS AND A NON-MYELOABLATIVE RE-
DUCED INTENSITY CONDITIONING ALLOGENEIC TRANSPLANTS INTE-
GRATED IN STANDARD OR DOSE DENSE THERAPY FOR BREAST CAN-
CER: COST-EFFICIENCY ANALYSES SUPPORT DESIGN OF COST-
EFFICIENT THERAPIES
Van Hoef, M.E.H.M.1 1Transplant Creations, Amsterdam, NH, Neth-
erlands.
Introduction: DFS at 5 yr in LN BrCa depends on status at
diagnosis and is on average 60% and in MBrCa 15%. HD-auto-Tx
add signiﬁcant DFS advantage of 5% to 10% but statistically this is
not a signiﬁcant improvement of survival. In large series TRM of
HD-auto-Tx is on average 3% in the adjuvant and up to 10% in the
metastatic setting. Semi-HD is rarely associated with TRM. Alloge-
neic transplants (allo-Tx) induce an immune response in BrCa that
may eradicate minimal residual disease if the Tx is administered in
molecular remission. Based on these facts and existent collaborative
patterns we designed in 2000 a treatment plan consisting of dose
dense induction, two semi-HD-auto-Tx and a NMRICTx and de-
cided to perform upfront cost computation.
Methods: In the Netherlands a cost system is used consisting of so
named “diagnose behandelingscombinaties” (DBC) or diagnosis
treatment combinations. In general costs are to be collected for each
item or service independently. We used the therapeutic model de-
scribed here above to compute the costs of treatment and used as-
sumption based on literature data to deﬁne disease outcome at 5 yr for
premenopausal women with ER, her-2-neu negative BrCa. For
each therapy median DFS was used to deﬁne outcomes. Disease
outcomes were deﬁned as alive without disease, alive with disease,
death and toxic death. Utilities for treatment and outcome were
derived from literature; The approach followed our Markov model
design of 2001.
Results: Disease outcomes at 5 yr of LN  BrCa by respectively 4
cycles induction ChT (1), two semi-HD- auto-Tx (2) and a non-
myeloablative reduced intensity conditioning Tx (3) with donor were
anticipated to be 60%, 70% and 90% without and 15% with relapse.
DBCwere identiﬁed and included costs for ﬁrst, second and third line
ChT on outpatient basis, or with a hospital episode, costs of hormonal
therapy, of a visit without procedure, of auto- and allo- stem cell
mobilization and leukapheresis, of auto-and allo-Tx, of post Tx care,
of follow-up, of terminal care. We adjusted for the fact that the DBC
costs are based on HD- and ablative ChT whereas our approach uses
semi-HD andNMRIC respectively. The computations of the cost per
treatment with follow-up of ﬁve years showed that standard/dose
dense ChT followed by hormonal therapy adds up to  100,000 and
that Tx types add each  50,000 by use of adjusted rates for HD-/
ablative Tx.
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